Phibro Animal Health Corporation (NASDAQ:PAHC) Given Consensus Rating of “Hold” by Brokerages

Phibro Animal Health Corporation (NASDAQ:PAHC) has been assigned an average recommendation of “Hold” from the five analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $42.50.

Several research firms have weighed in on PAHC. Weiss Ratings lowered Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Wall Street Zen cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Citigroup decreased their price objective on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th.

Insider Activity at Phibro Animal Health

In related news, CEO Jack Bendheim sold 4,528 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total value of $219,562.72. Following the sale, the chief executive officer directly owned 56,152 shares of the company’s stock, valued at approximately $2,722,810.48. The trade was a 7.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,648 shares of company stock worth $1,377,432 in the last quarter. Company insiders own 50.13% of the company’s stock.

Institutional Trading of Phibro Animal Health

Several hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Phibro Animal Health by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after buying an additional 546 shares during the period. Millennium Management LLC raised its position in Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after buying an additional 154,281 shares during the last quarter. Jane Street Group LLC lifted its stake in Phibro Animal Health by 65.3% in the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after acquiring an additional 13,404 shares in the last quarter. Cetera Investment Advisers lifted its stake in Phibro Animal Health by 63.0% in the 2nd quarter. Cetera Investment Advisers now owns 18,830 shares of the company’s stock valued at $481,000 after acquiring an additional 7,280 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Phibro Animal Health by 2.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after acquiring an additional 363 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Stock Performance

Shares of NASDAQ:PAHC opened at $34.03 on Tuesday. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97. Phibro Animal Health has a 1-year low of $25.58 and a 1-year high of $60.08. The stock has a market capitalization of $1.38 billion, a P/E ratio of 14.61, a P/E/G ratio of 0.48 and a beta of 0.46. The business has a 50-day moving average price of $32.45 and a two-hundred day moving average price of $43.26.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. The firm had revenue of $383.54 million during the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Equities analysts predict that Phibro Animal Health will post 3.08 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd were issued a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.4%. The ex-dividend date was Wednesday, June 3rd. Phibro Animal Health’s dividend payout ratio is 20.60%.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.